Heathbridge Capital Management Ltd. Sells 2,100 Shares of Haleon plc (NYSE:HLN)

Heathbridge Capital Management Ltd. decreased its stake in Haleon plc (NYSE:HLN) by 0.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,125,400 shares of the company’s stock after selling 2,100 shares during the period. Haleon makes up 4.5% of Heathbridge Capital Management Ltd.’s portfolio, making the stock its 11th largest holding. Heathbridge Capital Management Ltd.’s holdings in Haleon were worth $11,907,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. Cultivar Capital Inc. bought a new stake in shares of Haleon in the second quarter valued at about $40,000. Allspring Global Investments Holdings LLC bought a new position in shares of Haleon during the 1st quarter worth about $43,000. GAMMA Investing LLC lifted its stake in Haleon by 151.3% during the first quarter. GAMMA Investing LLC now owns 6,106 shares of the company’s stock worth $52,000 after purchasing an additional 3,676 shares during the period. Pinnacle Bancorp Inc. boosted its stake in Haleon by 29.8% in the 1st quarter. Pinnacle Bancorp Inc. now owns 6,188 shares of the company’s stock valued at $53,000 after buying an additional 1,421 shares in the last quarter. Finally, Hexagon Capital Partners LLC boosted its stake in shares of Haleon by 66.6% in the 2nd quarter. Hexagon Capital Partners LLC now owns 6,695 shares of the company’s stock valued at $55,000 after purchasing an additional 2,677 shares in the last quarter. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

HLN has been the topic of a number of research analyst reports. UBS Group upgraded Haleon to a “strong-buy” rating in a research report on Tuesday, October 1st. Berenberg Bank began coverage on shares of Haleon in a report on Tuesday, August 6th. They set a “buy” rating for the company. The Goldman Sachs Group downgraded shares of Haleon from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 6th. Finally, Morgan Stanley boosted their target price on Haleon from $9.90 to $10.95 and gave the company an “overweight” rating in a research note on Friday, September 20th. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Haleon presently has an average rating of “Buy” and an average price target of $10.95.

Haleon Stock Down 0.5 %

Shares of HLN stock opened at $10.08 on Friday. The company has a market capitalization of $46.03 billion, a price-to-earnings ratio of 33.60, a P/E/G ratio of 2.93 and a beta of 0.26. Haleon plc has a 12-month low of $7.70 and a 12-month high of $10.80. The firm has a fifty day moving average of $10.21 and a 200-day moving average of $9.12. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44.

Haleon (NYSE:HLN) last released its earnings results on Thursday, August 1st. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The firm had revenue of $3.50 billion for the quarter, compared to the consensus estimate of $3.55 billion. Haleon had a return on equity of 13.15% and a net margin of 9.71%. During the same quarter last year, the company posted $0.08 EPS. As a group, equities research analysts predict that Haleon plc will post 0.47 earnings per share for the current fiscal year.

Haleon Cuts Dividend

The company also recently announced a semi-annual dividend, which was paid on Thursday, September 19th. Shareholders of record on Friday, August 16th were paid a $0.0514 dividend. This represents a yield of 1.6%. The ex-dividend date of this dividend was Friday, August 16th. Haleon’s payout ratio is 33.33%.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.